Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

JAK inhibitors and systemic sclerosis: A systematic review of the literature
Clothilde Moriana, T. Moulinet, R. Jaussaud, et al.
Autoimmunity Reviews (2022) Vol. 21, Iss. 10, pp. 103168-103168
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

JAK inhibitors and autoimmune rheumatic diseases
Maurizio Benucci, Pamela Bernardini, Carmela Coccia, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 4, pp. 103276-103276
Open Access | Times Cited: 64
An updated review of the immunological mechanisms of keloid scars
Chih-Chun Lee, Chia-Hsuan Tsai, Chih‐Hao Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis
Maheswari Muruganandam, Angie Ariza‐Hutchinson, Rosemina A Patel, et al.
Journal of Inflammation Research (2023) Vol. Volume 16, pp. 4633-4660
Open Access | Times Cited: 19
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review
Aishwarya Muddebihal, Ananta Khurana, Kabir Sardana
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 279-295
Closed Access | Times Cited: 17
Novel and potential future therapeutic options in systemic autoimmune diseases
Lili Balogh, Katalin Oláh, Soma Sánta, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
The current landscape of antifibrotic therapy across different organs: A systematic approach
Isabel Fuster‐Martínez, Sara Calatayud
Pharmacological Research (2024) Vol. 205, pp. 107245-107245
Open Access | Times Cited: 6
Down-regulation of KLF2 in lung fibroblasts is linked with COVID-19 immunofibrosis and restored by combined inhibition of NETs, JAK-1/2 and IL-6 signaling
Akrivi Chrysanthopoulou, Christina Antoniadou, Anastasia‐Maria Natsi, et al.
Clinical Immunology (2023) Vol. 247, pp. 109240-109240
Open Access | Times Cited: 15
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review
Michela Gasparotto, Chiara Franco, Elisabetta Zanatta, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 6, pp. 103334-103334
Open Access | Times Cited: 14
Pathogenesis of Inflammation in Skin Disease: From Molecular Mechanisms to Pathology
Simona N. Shirley, A. Watson, Nabiha Yusuf
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10152-10152
Open Access | Times Cited: 4
Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib
F.S. Gillesberg, Martin Pehrsson, Anne‐Christine Bay‐Jensen, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The role and mechanism of JAK2 inhibitor in endothelial mesenchymal transition in systemic sclerosis
Qingyan Luo, Xiaoheng Wang, Yanling Zhang, et al.
Journal of Dermatological Science (2025)
Closed Access
Healing of the Toe Ulcers in Systemic Sclerosis
Wei Fan, Shufan Wu, Yi Zhang, et al.
International Journal of Rheumatic Diseases (2025) Vol. 28, Iss. 2
Closed Access
Systemic pharmacotherapy approaches for the treatment of systemic sclerosis
Stefano Di Donato, Zsuzsanna H. McMahan, Michael Hughes
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Neutrophils in autoimmunity: when the hero becomes the villain
Samal Bissenova, Darcy Ellis, Chantal Mathieu, et al.
Clinical & Experimental Immunology (2022) Vol. 210, Iss. 2, pp. 128-140
Open Access | Times Cited: 19
JAK inhibitors in rheumatology
Kunihiro Yamaoka, Kenji Oku
Immunological Medicine (2023) Vol. 46, Iss. 3, pp. 143-152
Open Access | Times Cited: 12
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib
Kristina Jevnikar, Polona Jaki Mekjavić, Nataša Vidović Valentinčič, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 9, pp. e273-e275
Closed Access | Times Cited: 3
Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box
Durga Prasanna Misra, Gaurav Pande, Vikas Agarwal
Clinical Rheumatology (2022) Vol. 42, Iss. 2, pp. 621-632
Closed Access | Times Cited: 15
Advances in biological and targeted therapies for systemic sclerosis
Erica Mulcaire-Jones, Andrea Hsiu Ling Low, Robyn T. Domsic, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 4, pp. 325-339
Closed Access | Times Cited: 8
Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders
L. Corbella‐Bagot, Constanza Riquelme‐Mc Loughlin, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas (2023) Vol. 114, Iss. 9, pp. 784-801
Open Access | Times Cited: 8
Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data
Elisa Fiorentini, Francesco Bonomi, Silvia Peretti, et al.
Life (2022) Vol. 12, Iss. 12, pp. 2101-2101
Open Access | Times Cited: 13
Effect of P. corylifolia on the pharmacokinetic profile of tofacitinib and the underlying mechanism
Yu Tian Wang, Quan Zhou, Huihui Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study
Marie Solignac, Natalia Cabrera, Marine Fouillet-Desjonquères, et al.
Journal of Autoimmunity (2024) Vol. 147, pp. 103248-103248
Open Access | Times Cited: 2
Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children
Özlem Şatırer, Jörg Henes, Michaela Döring, et al.
RMD Open (2024) Vol. 10, Iss. 3, pp. e004381-e004381
Open Access | Times Cited: 2
Critical Analysis of Cytoplasmic Progression of Inflammatory Signaling Suggests Potential Pharmacologic Targets for Wound Healing and Fibrotic Disorders
Michael L. Samulevich, Liam E. Carman, Brian J. Aneskievich
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2723-2723
Open Access | Times Cited: 2
Recent Advances in Treatment of Systemic Sclerosis and Morphea
Noelle Teske, Nicole Fett
American Journal of Clinical Dermatology (2023) Vol. 25, Iss. 2, pp. 213-226
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top